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Abstract
Background: The common cold questionnaire (CCQ) is used to discriminate those with and without a viral infection. Its
usefulness in people with acute asthma is unknown. Our aim was to assess the ability of the CCQ to detect viral infection
and to monitor recovery during a viral induced asthma exacerbation and confirmed by virological testing.
Methodology/Principal Findings: We studied subjects ($7 yrs) admitted to hospital with acute asthma and diagnosed as
positive (n=63), or negative to viral infection (n=27) according to molecular and virological testing from respiratory
samples. CCQ, asthma history and asthma control questionnaires were completed and repeated 4–6 weeks later. Sensitivity,
specificity, and response to change of the CCQ were assessed by receiver operator curve (ROC) analysis and effect size
calculation respectively. The CCQ did not discriminate between viral and non-viral infection for subjects with asthma
(sensitivity=76.2%; specificity=29.6%). ROC analysis could not differentiate between positive or negative virus in subjects
with asthma. The CCQ had a large response to change following recovery (effect size=1.01). 39% of subjects recovering
from viral exacerbation remained positive to virological testing at follow-up despite improvement in clinical symptoms. The
CCQ reflected clinical improvement in these subjects, thus providing additional information to complement virological
testing.
Conclusions/Significance: The CCQ is a useful instrument for monitoring response to viral infection in people with asthma.
Reliable differentiation between viral and non-viral asthma exacerbations was not achieved with the CCQ and requires
specific virological testing. When combined with virological testing, the CCQ should be a useful outcome measure for
evaluating therapies in viral-induced asthma.
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Introduction
Respiratory viral infections are the most common cause of asthma
exacerbations in both adults and children [1,2]. Rhinovirus is the
most common virus associated with the common cold and is also the
most common virus implicated in asthma exacerbations [1,2]. There
is a need to quantify cold symptoms in the assessment of an asthma
exacerbation, both to detect viral causes and to monitor progress.
These measures are especially needed to evaluate responses in
treatment studies. Several scales have been developed to discriminate
those with and without a viral infection [3], monitor symptoms in
response to treatment of the common cold [4], and to assess the
impact of symptoms on quality of life [5,6] and disease severity [7,8]
in people without asthma. However, the ability of these question-
naires to discriminate viral infection in acute asthma from a non-
infectious exacerbation is not known, and their responsiveness in
acute asthma is also unknown. This needs to be directly evaluated
since the overlap between symptoms of asthma and common cold
symptoms could limit the utility of common cold questionnaires in an
asthma exacerbation. Such measures may be particularly important
in the assessment of anti-viral and anti-inflammatory therapies in
asthma exacerbations. The aims of this study were to assess whether
the common cold questionnaire (CCQ) [9] could detect a respiratory
viral infection during asthma exacerbation in both adults and
children, and to describe the ability of the CCQ to monitor recovery
from a viral induced asthma exacerbation.
Materials and Methods
Subjects
Eligible subjects were participants in a study of virus-induced
asthma where the common cold questionnaire was administered
and samples were collected for viral detection by molecular
diagnosis. Adults and children $7 years admitted to John Hunter
Hospital (Newcastle, Australia) experiencing an acute exacerbation
of asthma were recruited between February 2001 and May 2005
(n=90), a subset of which have been previously reported [10].
Exclusion criteria were age less than 7 years.
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Participants attended for two study visits. Firstly during the
acute admission for asthma, and secondly at recovery, 4–6 weeks
later. At each visit participants completed the common cold
questionnaire (CCQ) [3,9], information on asthma history, an
asthma control questionnaire[11], provided nasal/throat swabs,
and underwent skin prick allergen testing and spirometry. Induced
sputum was collected after ultrasonic nebulisation of isotonic saline
as previously described [12,13,14]. Subjects were diagnosed as
positive or negative to respiratory viral infection according to
molecular and virological testing [10]. Written informed consent
was obtained from all participants in this study, which was
approved by the Hunter Area Health Service and University of
Newcastle Research Ethics Committees.
The Common Cold Questionnaire
The CCQ used in this study was adapted from that used as part
of the Common Cold Unit’s standard protocol [3,9]. It records
symptoms across four domains: general symptoms; nasal symp-
toms; throat symptoms; and chest symptoms (Table 1). Symptoms
are scored using a 4-point category scale as none=0, mild=1,
moderate=2 or severe=3 and summed with a maximum total
score of 27. Subjects were classified by CCQ as ‘no virus’ if there
were no symptoms, as a ‘possible virus’ if they had mild symptoms
in one domain plus a cough, and as a ‘probable’ virus if there were
moderate symptoms in at least two domains or mild symptoms in
three domains. The asthma history questionnaire detailed the age
of diagnosis and the history of the subject’s asthma over the past
year. This included the number of exacerbations, doctor and
hospital visits, episodes of worsened asthma and the number of
days missed from work or school due to asthma. Asthma control
was assessed over the previous week using an asthma control
questionnaire that scored symptoms, activity limitation and rescue
beta agonist use on a 0–6 scale[11].
Specimen Processing
Lower respiratory portions were selected from induced sputum
samples and placed in an RNA lysis buffer (Buffer RLT-Qiagen,
Hilden, Germany) as previously described [10]. Nasal swabs and
throat swabs were also immersed in Buffer RLT. Extraction and
purification of sputum, swab RNA was performed using the
RNeasy kit (Qiagen) as per manufacturer’s instructions. RNA was
then reverse-transcribed to total cDNA using random primers and
the Superscript II RT kit (Invitrogen, Carlsbad, USA).
Samples were assayed for the presence of rhinovirus (RV),
enterovirus (EV), influenza virus types A and B (IFA, IFB),
respiratory syncytial virus types A and B (RSVA, RSVB), non-
SARS coronavirus (CoV) and human metapneumovirus (MPV)
virus RNA transcripts. Using the gel-based PCR assays [10] or
real-time ‘TaqMan’ methodology PCR assays (RV[15], EV[16],
RSVA & RSVB[17], hMPV[18], CoV). All TaqMan assays
proceeded using 12.5% of the cDNA product and the Eppendorf
RealMasterMix Probe ROX kit (Eppendorf AG, Hamburg,
Germany), all with the same cycling parameters, namely: 2 min
at 95uC to activate HotMaster Taq DNA polymerase and 40
cycles of 95uC for 15 sec followed by 1 min at 60uC (ABI 7500
cycler; Applied Biosystems, Foster City, CA, USA). Subjects were
considered virus positive if a virus was detected by direct molecular
detection in sputum, swab (nasal or throat) or saliva.
Statistical Analysis
Analysis was performed using Stata 7 (Stata Corporation,
College Station, Texas USA), with results presented as median
(interquartile range) or n (%) as appropriate. Differences in subject
characteristics and common cold score between virus positive and
virus negative groups were determined (significance=p,0.05)
from non-parametric Wilcoxon ranksum test, Kruskall Wallis test
or Fisher’s exact test and Chi-square test. Paired analyses were
conducted using Wilcoxon sign rank test.
Receiver operator curve (ROC) analyses were used to evaluate
different diagnostic cut-off levels for the CCQ score for all subjects
and for adults ($16 years) and children (,16 years) separately.
Sensitivity, specificity, positive and negative predictive values and
likelihood ratios were used to describe the discriminant validity of
the CCQ for determining a ‘probable virus’ versus a ‘no virus’ or
‘possible virus’.
The ability of the CCQ to respond to a change in health status
in virus infected subjects was evaluated by calculating the effect
size as described by Cohen et al [19]. The effect size is the mean
difference between the scores at the first and follow up visits
divided by the standard deviation at the first visit. An effect size of
0.8 or more is considered a large response to change [19].
Table 1. Common Cold Questionnaire
In the 2 days prior to admission with asthma, has the subject experienced any of the following symptoms? Please circle the severity of the symptoms experienced.
General Symptoms: 1. Fevers None Mild Moderate Severe
2. Chills None Mild Moderate Severe
3. Muscle pains None Mild Moderate Severe
Nasal Symptoms: 1. Watery eyes None Mild Moderate Severe
2. Runny nose None Mild Moderate Severe
3. Sneezing None Mild Moderate Severe
Throat Symptoms: 1. Sore throat None Mild Moderate Severe
Chest Symptoms: 1. Cough None Mild Moderate Severe
2. Chest pain None Mild Moderate Severe
A ‘probable’ viral infection is where there are moderate symptoms noted in at least 2 of the above 4 categories or mild symptoms noted in 3 or more categories.
A ‘possible’ viral infection is where mild symptoms are noted in one category plus a cough. Scoring: none=0, mild=1, moderate=2, severe=3. Total score equals the
sum of all scores
doi:10.1371/journal.pone.0001802.t001
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Data were collected 1.3 (0.8), mean (SD), days post admission.
Respiratory virus infection was present in 63 (70%) subjects, with a
negative respiratory virus result in 27 (30%) subjects. The viruses
detected were: rhinovirus (n=52, 83%), enterovirus (n=18, 29%),
RSV (n=1, 2%), Influenza A (n=5, 8%) and Influenza B (n=2,
3%). In 14 subjects dual viruses were detected and in one subject
three different viruses were detected. Table 2 describes the subject
characteristics for the virus positive and virus negative groups.
There was no difference in the proportion of subjects with atopy,
smoking status or gender between the groups. Those with a
positive virus result had a lower percent predicted FEV1, were
younger than the virus negative group and had a similar asthma
control score (Table 2).
Common Cold Questionnaire Scores
The CCQ scores by domain and subject group are described in
Table 3. The questionnaire identified a similar proportion in both
the viral and non-viral groups as having a ‘probable virus’ or ‘no
virus’ (p=0.802). Total score, general, nasal, throat and chest
domainscores were similar for both viruspositiveand virus negative
groups (Table 3). However a significantly higher total score was
evident in the virus positive group for adults but not children.
The total CCQ score demonstrated a weak and clinically
significant correlation to asthma control score (spearman’s rho
(95%CI)=0.35 (0.14 to 0.53), Figure 1). There was no correlation
between total CCQ score and percent-predicted FEV1 (spear-
man’s rho=0.03, p=0.821) and no significant difference in score
between exacerbations classified as mild, moderate, or severe
based on their percent-predicted FEV1 at admission ($80%;
$60,80%; ,60%) (p=0.08).
CCQ and Viral Detection
The ability of the CCQ to detect a respiratory virus infection in
subjects with asthma, adults and children is displayed in Table 4.
The CCQ was scored and results categorised as a ‘probable virus
infection’ compared to a ‘no infection’ or ‘possible virus infection’
result. For all subjects, both adults and children, moderate
sensitivity was traded against poor specificity and low negative
predictive values (Table 4). A CCQ result of ‘probable virus
infection’ did have a good positive predictive value for viral
infection in children.
ROC analysis was unable to determine an appropriate CCQ score
to discriminate between a virus positive and virus negative result for
all subjects or adults or children separately (Figure 2a, 2b, 2c).
A sensitivity analysis was conducted by excluding the chest
symptom domain from the ROC analysis to account for the
possible confounding effect that these symptoms may have in
people with asthma with or without a virus (Figure 2d). This did
not improve the ability of the CCQ to discriminate between virus
positive and virus negative subjects (AUC=0.533, p=0.619).
Response to Change in Health Status
The CCQs response to change following recovery from a
respiratory virus infection was large (Figure 3). The effect size
calculated between the first and follow up visit at 4–6 weeks for 33
subjects who were virus positive was 1.01. This was in conjunction
with significant clinical improvements in FEV1 percent predicted
(mean (SD) 21.4(19.1)%, p,0.0001) and asthma control score
(21.6 (1.2), p,0.0001). However on molecular testing 13 (39%)
remained positive to virus. These 13 subjects who remained virus
Table 2. Characteristics of subjects with Asthma
Exacerbations
Virus negative
by PCR
Virus positive
by PCR P-value*
n2 7 6 3
Age, median (IQR) 28.7 (16.5, 52.6) 13.6 (9.8, 37.1) 0.007
Sex (M/F) 11/16 22/41 0.600
Smoker, n (%) 5 (19.2) 8 (13.3) 0.483
Atopy, n (%) 15 (88.2) 44 (89.8) 1.0
FEV1 percent predicted,
median (IQR)
70.0 (56.0, 80.9) 62.0 (46.4, 70.0) 0.075
Asthma control score,
mean (SD)
3.26 (1.34) 2.84 (1.34) 0.183
#
IQR: interquartile range
*chi-square test or Wilcoxon ranksum test;
# Student’s t test
doi:10.1371/journal.pone.0001802.t002
Table 3. Common Cold Questionnaire (CCQ) Scores During
Asthma Exacerbation for all Subjects.
Virus
negative
by PCR
Virus
positive
by PCR P-value
n2 7 6 3
CCQ No virus, n(%) 4 (14.8) 8 (12.7) 0.802*
Possible virus, n(%) 4 (14.8) 7 (11.1)
Probable virus, n(%) 19 (70.4) 48 (76.2)
Total score All subjects 7 (5, 13) 9 (5, 13) 0.628
Adults (n=48) 6 (1, 10) 10 (7, 13) 0.009
Children (n=42) 4 (2, 11) 7.5 (4, 11) 0.449
General
symptoms score
1 (0, 5) 1 (0, 3) 0.711
Nasal Symptoms
score
2 (0, 4) 3 (1, 5) 0.219
Throat symptoms
score
1 (0, 2) 1 (0, 2) 0.156
Chest symptoms
score
2 (2, 4) 3 (1, 5) 0.921
Results are median (IQR), Wilcoxon ranksum test. * Fisher’s exact test
doi:10.1371/journal.pone.0001802.t003
Figure 1. Correlation of Common Cold Total Score and Asthma
Control Score for all Subjects
doi:10.1371/journal.pone.0001802.g001
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CCQ total score, FEV1 percent predicted and asthma control
score (Table 5).
Discussion
In this study we have been the first to examine the validity of the
CCQ to differentiate between viral and non-viral exacerbations of
asthma in both adults and children using molecular diagnostics to
confirm the viral infection. Although median CCQ scores were
higher in viral infection in adults, the CCQ did not discriminate
sufficiently well between viral and non-viral exacerbations of
asthma. In contrast the CCQ performed very well in monitoring
recovery of the viral infection, providing additional information to
an asthma symptom score. This suggests a useful role for the CCQ
in treatment studies, when combined with virological diagnosis.
The majority of our subjects were recruited as inpatients with an
acute exacerbation of asthma and were a population with
significant disease, in whom discrimination of viral and non-viral
causes would be useful. The CCQ performed poorly in
discriminating between a viral and non-viral exacerbation in
people with acute asthma. The poor discrimination of the CCQ in
Table 4. Performance Characteristics of the Common Cold Questionnaire for Virus Infection
+
Tests Sensitivity (95%CI) Specificity (95%CI) PPV (95%CI) NPV (95%CI) +ve LR (95%CI) -ve LR (95%CI)
All asthma 76.2% (63.5 to 85.6) 29.6% (14.5 to 50.3) 71.6% (59.1 to 81.7) 34.8% (17.2 to 57.2) 1.08 (0.82 to 1.43) 0.80 (0.43 to 1.49)
Adults 85.2 % (65.4 to 95.1) 23.8% (9.1 to 47.5) 59.1% (42.2 to 74.0) 55.6% (22.7 to 84.7) 1.12 (0.84 to 1.49) 0.62 (0.19 to 2.07)
Children 69.4% (51.7 to 83.1) 50.0% (13.9 to 86.1) 89.2% (70.6 to 97.2) 21.4% (5.7 to 51.2) 1.39 (0.61 to 3.18) 0.61 (0.27 to 1.39)
PPV: positive predictive value
NPV: negative predictive value
LR: Likelihood ratio
+Common cold questionnaires were scored as ‘probable virus’ or ‘no or possible virus’ as per methods.
doi:10.1371/journal.pone.0001802.t004
Figure 2. Receiver Operator Curves for Common Cold Score and Virus Result. A: CCQ (all asthma); B: CCQ (adults); C: CCQ (children); D: CCQ
(excl chest symptoms).
doi:10.1371/journal.pone.0001802.g002
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setting. Many subjects scored as ‘probable virus’ according to the
CCQ but were negative to virus by molecular diagnostic testing.
The poor fitting ROC curve indicated that there was no obvious
CCQ score that was diagnostic (Figure 2a).
This is perhaps not surprising, given the limitations to viral
diagnostics, even when using PCR. It is therefore possible that
respiratory viruses could have been responsible for the exacerba-
tion, but went undetected either because of assay sensitivity or
infection with as yet unidentified viruses. The lack of discrimina-
tion in CCQ score was evident for both adults and children. To
exclude the possibility that the common symptoms of cough in
asthma may be confused for cold symptoms, further ROC analysis
was conducted excluding the chest symptoms domain. However
this did not improve the diagnostic ability of the CCQ in asthma
exacerbations (Figure 2d).
The low specificity for the CCQ in asthma may be due to
several additional factors. People with asthma respond to other
triggers that can cause nose symptoms such as allergens, and
rhinitis is a common comorbidity in asthma. Chest symptoms are
also a feature of an asthma exacerbation, and constitute one of the
domains of the CCQ. Thus non-infectious exacerbations of
asthma could cause chest symptoms and reduce the specificity of
the CCQ. Recent data indicate an altered pathogenesis of viral
infection in asthma compared to controls. RV infection is
considered to be an upper airway infection. However, people
with asthma experience lower respiratory symptoms more often in
viral infection [20] and RV is frequently isolated from the lower
respiratory tract in asthma [21,22,23]. This altered pathogenesis
may be due to impaired innate antiviral responses in the
respiratory epithelium in asthma [24]. The result is a greater
overlap between common cold and asthma symptoms. Conse-
quently there are several possible explanations for the limited
discriminant validity of the CCQ in asthma.
The relationship between CCQ scores and asthma severity was
assessed using two severity measures: percent-predicted FEV1 and
asthma control score. There was no relationship between CCQ
score and severity of airflow obstruction (FEV1) during the
exacerbation; however, CCQ was weakly correlated to asthma
control score. This may be due to an association between asthma
symptoms, severity and CCQ in acute asthma, or an overlap in
symptoms assessed by the two questionnaires.
The CCQ did prove useful in monitoring symptoms over time
in asthma. The response of the CCQ to a change in health status
exceeded the large response (.0.8) considered to be clinically
useful by Cohen [19]. The effect size indicates that in people with
asthma the CCQ has a high response to change following a viral
infection. This validates the use of the CCQ to monitor recovery
and indicates the potential usefulness of this tool in monitoring
clinical recovery post viral infection, and as an evaluative tool in
treatment studies [25].
At recovery, 39% of subjects remained positive to virological
testing despite an improvement in clinical symptoms. The CCQ
may be a more sensitive reflection of clinical improvement
following viral infection in people with asthma and may provide
additional information when monitoring response to treatment.
The CCQ is an attractive instrument for monitoring response to
viral infection in asthma due to viral infections. However the CCQ
is not able to reliably differentiate between viral and non-viral
asthma exacerbations. The combination of viral diagnosis and the
CCQ should prove useful for the evaluation of antiviral and other
therapies in asthma exacerbations.
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